Gentiana straminea iridoids gentiopicroside and swertiamarin bind STAT3, modulating RA inflammatory pathways.

Current treatments for rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease, often involve disease-modifying antirheumatic drugs (DMARDs) and biologics, which can have significant side effects or limited efficacy for some patients. There is a continuous need for novel therapeutic agents, particularly those derived from natural sources, to offer safer and more effective alternatives. Traditional medicinal plants, like Gentiana straminea, have been historically used for anti-arthritic purposes, but their active components and precise mechanisms of action against RA remain largely uncharacterized. Understanding these mechanisms could unlock new drug development pathways targeting key inflammatory mediators.

Researchers employed an integrated strategy to investigate the pharmacodynamic basis of Gentiana straminea against RA. First, UHPLC-Q-TOF-MS/MS was used to characterize and identify the core components absorbed into the blood after administration. Subsequently, network pharmacology predicted potential therapeutic targets and biological processes related to RA. Molecular docking simulations were then performed to assess the binding potential of the identified core components with key predicted targets. Finally, bio-layer interferometry provided quantitative validation of the specific molecular interactions, measuring binding affinities between the active compounds and selected protein targets.

The UHPLC-Q-TOF-MS/MS analysis identified gentiopicroside, swertiamarin, and loganic acid as the primary active components of Gentiana straminea absorbed into the bloodstream. Network pharmacology predicted these components are primarily involved in RA-related biological processes, including inflammatory response and immune cell activation. Molecular docking studies indicated favorable binding potential between these core components and key targets such as STAT3, EGFR, and MMP9. The most significant finding came from quantitative validation using bio-layer interferometry:

Gentiopicroside demonstrated specific binding to STAT3 with a high affinity, measured at a KD of 50.1 nmol·L^(-1). Similarly, swertiamarin also exhibited specific, high-affinity binding to STAT3, with a KD of 87.7 nmol·L^(-1). These results strongly suggest that the iridoid components of G. straminea exert anti-RA effects by directly targeting STAT3 and subsequently modulating associated inflammatory pathways.